Quantum Technology Governance I : Law and Regulation

This Open Access book, the first volume in a two-part series on quantum technology governance, provides a systematic examination of the legal and regulatory dimensions of quantum technologies, offering an original contribution to the emerging discourse on quantum governance. It distinguishes itself as one of the first comprehensive analyses to explore how quantum technologies intersect with existing legal frameworks, addressing the implications of quantum advancements for law, policy, and regulatory practice. The work examines how developments in quantum computing, cryptography, and sensing challenge established approaches to intellectual property, cybersecurity regulation, export controls, and public international law, while identifying pathways for adapting and strengthening existing governance structures. It highlights how the non-classical features of quantum technologies stress-test conventional legal doctrines and require interpretive flexibility, anticipatory policymaking, and evidence-based regulatory strategies rather than wholesale reform. Grounded in developments through 2025, the volume equips policymakers with analytical tools to navigate legal uncertainty, balance innovation with risk, and address regulatory gaps in areas such as cybersecurity and export controls, while fostering coordinated responses at national and international levels. The book equips scholars, policymakers, and practitioners with conceptual and practical insights to evaluate the evolving interplay between technological innovation, security, and legal order in the quantum era. With an interdisciplinary perspective, it advances understanding of how legal and regulatory systems can respond to the technical and governance challenges posed by quantum technologies.

Mateo Aboy is Director of Research in Biomedical Innovation, AI, QT & Law at the Faculty of Law, University of Cambridge. He is a member of the Centre for Law, Medicine & Life Sciences (LML) and the Centre for IP & Information Law (CIPIL) at the University of Cambridge. He holds degrees in electrical & computer engineering (BS, BSEE, MSECE, MPhil/DEA, PhD ECE), law (LLB, SJD/PhD/LLD), and international management (MBA), as well as professional registrations as a Professional Chartered Engineer (CEng, EU/ES COIT), Certified Licensing Professional (CLP), Patent Practitioner with a Bar Admission/licensed to practice in patent cases before the United States Patent Office (USPTO), Fellow of Information Privacy (FIT, IAPP), Certified Privacy Information Professional (CIPP/E), Certified Privacy Manager (CIPM), Lead Implementer of Information Security Management Systems-ISMS (ISO 27001), Lead Auditor of Medical Device Quality Management Systems (ISO 13485), Lead Implementer of Privacy Information Management Systems - PIMS (ISO 27701), and Certified Data Protection Officer (C-DPO).

Marcelo Corrales Compagnucci is Associate Professor and Associate Director at the Center for Advanced Studies in Bioscience Innovation Law (CeBIL), Faculty of Law, University of Copenhagen in Denmark. He is also Inter-CeBIL Research Affiliate at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. He specializes in information technology, privacy, and data protection law. His research interests are the legal issues involved in disruptive innovation technologies and biomedicine. He wasa research associate with the Institute for Legal Informatics (IRI) at Leibniz Universität Hannover in Germany, and a visiting research fellow in various research centers around the world, including Harvard Law School, Cambridge University, the Max Planck Institute, University of Edinburgh, Turin University, and the Academia Sinica in Taiwan. He has a Doctor of Laws (LL.D.) degree from Kyushu University in Japan. He also holds a Master of Laws (LL.M.) in international economics and business law from Kyushu University, and an LL.M. in law and information technology and an LL.M. in European intellectual property law, both from the University of Stockholm in Sweden.

Timo Minssen is Professor of Law at the University of Copenhagen (UCPH), specializing in Health & Life Science Innovation. He is Director of UCPH’s Center for Advanced Studies in Bioscience Innovation Law (CeBIL) and holds the UNESCO Co-Chair in the Right to Science. He is an Inter-CeBIL Research Affiliate at Harvard Law School and the University of Cambridge, and an Associate Member of McGill University’s Centre of Genomics and Policy.
   His research and practice focus on IP, competition, and regulatory law in emerging technologies, including AI, quantum technologies, advanced health & life science technologies, and biotechnologies. He holds a German law degree from the University of Göttingen and biotech/IP-focused LL.M., M.I.C.L., LL.Lic., and LL.D. degrees from Lund and Uppsala Universities. He has been trained in the German court system, the European Patent Office, and in law firms and start-ups. Previous roles include an Epigenetics fellowship at the Pufendorf Institute for Advanced Studies and visiting professorships at the Technical University of Munich, the Universities of Cambridge and Oxford, Waseda Law School, Harvard Law School, and the Max Planck Institute for Innovation & Competition. In 2007, he was Associate Professor at Chicago-Kent College of Law, teaching comparative European and US patent law.
  Timo is a Scientific Advisory Board Member of the Munich Intellectual Property Law Centre (MIPLC) and advises the WHO, WIPO, the European Commission, companies, national governments, and law firms. At UCPH he leads interdisciplinary projects spanning precision medicine, AI-assisted surgery, medical devices and ATMPs, antimicrobial resistance, pandemic preparedness, advanced medical computing, and sustainable innovation. He is PI and grant holder of a large Novo Nordisk Foundation–funded bioscience innovation law program with international core partners including Harvard, DTU, and the Universities of Cambridge and Michigan. His scholarship includes 8 books and 250+ publications and is frequently featured in outlets such as The Economist, Financial Times, El Mundo, Politico, Times of India, WHO Bulletin, and Times Higher Education.